FDA warns company to stop putting erectile dysfunction drugs in e-cigarette liquid – Washington Examiner

The Food and Drug Administration warned an e-cigarette manufacturer Thursday to stop putting the key ingredients of an erectile dysfunction drug and an anti-obesity drug into vaping liquid.

The warning letter is another part of a broad crackdown on e-cigarette makers and retailers meant to curb the growing use of the product among minors. But this is the first warning letter sent to a company for adding prescription drugs into an e-cigarette liquid, the agency said.

The letter was sent to HelloCig Electronic Technology Co. for selling two e-cigarette liquids, one containing the active ingredients of erectile dysfunction drug Cialis and the other the ingredients for anti-obesity drug Acomplia.

“These FDA-approved prescription drugs are not approved for inclusion in e-liquid products sold over the counter and are therefore being sold illegally,” the FDA said in a statement on the warning letter to HelloCig.

The FDA also warned the company for marketing the products in a misleading way. For instance, the liquid containing Cialis ingredients is marketed with an image of a Cialis bottle.

“Use of these trade names and images of the drug products next to the e-liquid products on HelloCig’s website suggests that the products are intended to treat the same conditions as the drug itself,” the FDA said.

It also said that HelloCig was illegally marketing some products as FDA-approved when they weren’t.

The agency requires e-cigarette manufacturers to apply for agency approval of a product that is on the market after a “grandfather” date of Feb. 15, 2007.

The FDA told the Washington Examiner it was not aware of an application from HelloCig for approval.

A request for comment from HelloCig on the application and the warning letter was not returned.

The agency gave the manufacturer 15 days to state how it will address the

Read More Here...

This entry was posted in Vaporizer E-Cigarette Stocks News. Bookmark the permalink. Follow any comments here with the RSS feed for this post. Trackbacks are closed, but you can post a comment.

Leave a Reply

Your email address will not be published. Required fields are marked *

Your email address will never be published.